Clinical Trial Update: Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial [Phase 2]

View source ↗

Summary

Phase 2 PRECISE trial evaluating rational epigenetic immunotherapy as second-line treatment for non-small cell lung cancer has completed and posted results. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Lung Cancer, Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-12-10